Glutathione: one small trial for the topical form; the oral form was not significant

This is a 2021 trial from Makassar, Indonesia. 46 people were split into two groups, one receiving oral placebo and one oral glutathione. Every participant also applied topical placebo to one side of the face and topical glutathione to the other.

Over 8 weeks, melanin index (MI) and L* were measured every two weeks with a mexameter and a chromameter — instrument readings, not a questionnaire.

The result: the combination group (oral plus topical) did significantly better than placebo on melanin index and L* (P < .05). The authors concluded the combination may beat either alone.

Three cautions in reading it.

First, the abstract does not state the concentration of the topical preparation. Without knowing what percentage was applied, there is no way to check whether a product on a shelf matches the trial. This site does not estimate concentrations it does not know.

Second, it ran 8 weeks. Pigment moves slowly, and a difference an instrument picks up at 8 weeks is not guaranteed to be a difference you see in a mirror.

Third, it enrolled 46 people, and it is the only randomised trial of topical glutathione we found. A single trial cannot rule out chance.

This is a 2021 multicentre trial in Indonesia, run at three teaching-hospital dermatology clinics. 83 people aged 33 to 50 completed it.

Participants were randomised to a glutathione supplement or placebo capsules for 12 weeks. Every four weeks, pigmented spots (ultraviolet and polarised) and skin tone were measured with a Janus facial analysis system.

Here is the result as reported.

Reductions in ultraviolet spots in certain subgroups, in polarised spots and in skin tone were larger in the glutathione group, but the difference was not statistically significant. The authors concluded it was 'slightly beneficial in particular subgroups, but the results were not statistically significant' and that further research is required.

And there is one more limitation built into the design. What people swallowed was not glutathione alone but a combination of glutathione plus ascorbic acid, alpha-lipoic acid and zinc.

So even if this trial had come out significant, it could not have told you which component did it. It did not come out significant, so that question never arose.

'Oral glutathione lightens skin' is not a sentence this trial supports.

A 2025 systematic review in the International Journal of Dermatology examined glutathione as a skin-lightening agent and in melasma.

The phrase that best captures where this ingredient stands comes from a 2026 review of all three routes — intravenous, oral and topical — which calls it an 'evidence-practice gap.'

It is a shape we meet often in this layer: a plausible mechanism is observed in the laboratory, the mechanism becomes the marketing copy, and the step of confirming it in people gets skipped.

That is not the same as 'it does not work.' It means the large, well-designed trial has not been done. And when something this widely sold has no such trial, that absence can itself mean somebody would be inconvenienced by an answer either way.

If you are looking for something for pigment, thiamidol, tranexamic acid and cysteamine are ahead of it on both the number and the design of their trials.

In Korea, nine ingredients are listed in the functional cosmetics review rule (Annex 4) as accepted for a 'helps whiten skin' claim without submitting efficacy data of your own: broussonetia extract, arbutin, ethyl ascorbyl ether, licorice extract (oil-soluble), ascorbyl glucoside, magnesium ascorbyl phosphate, niacinamide, alpha-bisabolol and ascorbyl tetraisopalmitate.

Glutathione is not on that list. A product making the claim would have to go through individual review.

The oral form sits in a different category again: supplements and cosmetics are governed by separate rules. Check the labelling to see which category a product falls under.